News
POA Pharma GmbH announces Medical Nutrition Scholarship Winners for 2024
27 Sep 2024
POA Pharma GmbH, a pharmaceutical company based in Sprockhövel, successfully ran its Medical Nutrition Scholarship for the second year. This year, the scholarship extended the applicant pool to Austria and the German Market. The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such [...]
POA Pharma announces expansion into Austria, deepening its inborn metabolic disease footprint in Europe
30 May 2024
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced the launch of PKU Easy Microtabs Plus in Austria.
This marks the latest milestone for POA Pharma, as it continues to expand its European footprint in the inborn metabolic disease (IMD) market, after launching the product in Germany...
POA Pharma GmbH announces Germany’s Medical Nutrition Scholarship Winners for 2023
01 Nov 2023
POA Pharma GmbH, a speciality pharmaceutical company based in Sprockhövel, has announced the winners of its Medical Nutrition Scholarship Award for 2023 as Emilie Göllner and Kim Hamberger.
The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinemia (TYR), [...]
POA Pharma announces the launch of PKU Easy Microtabs Plus into the European Market
11 Oct 2023
POA Pharma, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany and the Nordic region.
PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.
The new PKU EASY Microtabs...
POA Pharma announces launch of activities in Germany
20 Apr 2023
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced its expansion into Germany as POA Pharma GmbH.
POA Pharma, headquartered in Copenhagen with additional facilities located across the Nordic region, is part of Galen Limited. This privately owned company, which was established in 1968, has global headquarters [...]
POA Pharma, enters the German market, securing exclusive in-licensing rights for Rapilose Oral Glucose Solution (OGS)
19 Sep 2022
POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose OGS.
POA Pharma’s parent company, Galen Limited, a global pharmaceutical company, and proud member of the Almac Group, has an existing, long standing in-licensing relationship with Penlan...
Galen Medical Nutrition Announces Scholarship Award is open for applications
26 Jul 2021
Supporting patients with metabolic disorders accessing further education
Craigavon, U.K. – 27 Jul 2021 - Galen, the privately-owned pharmaceutical sales and marketing company, is pleased to announce the inaugural Galen Medical Nutrition Scholarship Award designed to support people with metabolic disorders, such as Phenylketonuria (PKU), accessing further education, training and development courses or apprenticeships.
Entrants [...]
Galen Announces Completion of Multi-Million Pound POA Pharma Acquisition
07 Jan 2020
Move adds substantial new therapeutic areas and territories to Galen’s reach
Craigavon, N.I., 8 Jan 2020 - Galen, the privately owned global pharmaceutical sales and marketing company, today announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and...